MiRNA-based therapy for Regenerating the lost cardiomyocytes in Myocardial patients: MiRNA-96 increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 21/November/2016, 8.10 pm

Natural product-based PD-1 pathway blockade for Human cancer therapy: γ-Bisabolene, found in Cardamom among others, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 21/November/2016, 11.17 am
November 21, 2016
Anti-telomerase cancer therapy: MiRNA-466g suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 21/November/2016, 11.22 pm
November 21, 2016
Show all

[easy_payment]Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761) by Prof Tzahor ED’Uva G, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Regenerating the lost cardiomyocytes in Myocardial patients: MiRNA-96 increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene


Significance

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease;  and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients.


From research findings to Therapeutic opportunity

This study suggests an MiRNA-based cardiac regeneration therapy. MiRNA-96 , by decreasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration.  

price-100

Thus, pharmacological formulations encompassing MiRNA-96 or its activators or MiR-96 plus any of the known compounds that promote cardiac regeneration may be used to promote cardiomyocyte regeneration following myocardial infarction


Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 100

Undisclosed (mechanistic insights) information: How MiR-96  increases the expression of  ERBB2/Her2

# Research cooperation


References

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L., MiRNA-based therapy for Regenerating the lost cardiomyocytes in Myocardial patients: MiRNA-96 increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 21/November/2016, 8.10 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org


Comments are closed.